131 related articles for article (PubMed ID: 8500532)
21. Adipsin/acylation stimulating protein system in human adipocytes: regulation of triacylglycerol synthesis.
Cianflone K; Roncari DA; Maslowska M; Baldo A; Forden J; Sniderman AD
Biochemistry; 1994 Aug; 33(32):9489-95. PubMed ID: 8068623
[TBL] [Abstract][Full Text] [Related]
22. The failure to show a necessary role for C3 in the in vitro antibody response.
Waldmann H; Lachmann PJ
Eur J Immunol; 1975 Mar; 5(3):185-93. PubMed ID: 1086224
[TBL] [Abstract][Full Text] [Related]
23. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
[TBL] [Abstract][Full Text] [Related]
24. Interaction of desialated guinea pig erythrocytes with the classical and alternative pathways of guinea pig complement in vivo and in vitro.
Brown EJ; Joiner KA; Frank MM
J Clin Invest; 1983 Jun; 71(6):1710-9. PubMed ID: 6863540
[TBL] [Abstract][Full Text] [Related]
25. Kallikrein Cleaves C3 and Activates Complement.
Irmscher S; Döring N; Halder LD; Jo EAH; Kopka I; Dunker C; Jacobsen ID; Luo S; Slevogt H; Lorkowski S; Beyersdorf N; Zipfel PF; Skerka C
J Innate Immun; 2018; 10(2):94-105. PubMed ID: 29237166
[TBL] [Abstract][Full Text] [Related]
26. Activation of complement pathways by univalent antibody derivatives with intact Fc zones.
Watts HF; Anderson VA; Cole VM; Stevenson GT
Mol Immunol; 1985 Jul; 22(7):803-10. PubMed ID: 3849671
[TBL] [Abstract][Full Text] [Related]
27. Complement factor D-like activity of Porphyromonas gingivalis W83.
Schenkein HA
Oral Microbiol Immunol; 1991 Aug; 6(4):216-20. PubMed ID: 1667434
[TBL] [Abstract][Full Text] [Related]
28. Detection and quantification of the control proteins of the alternative pathway of complement in 3T3-L1 adipocytes.
Peake PW; O'Grady S; Pussell BA; Charlesworth JA
Eur J Clin Invest; 1997 Nov; 27(11):922-7. PubMed ID: 9395788
[TBL] [Abstract][Full Text] [Related]
29. Defining the role of complement in experimental pemphigus vulgaris in mice.
Anhalt GJ; Till GO; Diaz LA; Labib RS; Patel HP; Eaglstein NF
J Immunol; 1986 Nov; 137(9):2835-40. PubMed ID: 3760574
[TBL] [Abstract][Full Text] [Related]
30. Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve.
Cook KS; Min HY; Johnson D; Chaplinsky RJ; Flier JS; Hunt CR; Spiegelman BM
Science; 1987 Jul; 237(4813):402-5. PubMed ID: 3299705
[TBL] [Abstract][Full Text] [Related]
31. In vivo anti-complementary activities of the cobra venom factors from Naja naja and Naja haje.
Van den Berg CW; Aerts PC; Van Dijk H
J Immunol Methods; 1991 Feb; 136(2):287-94. PubMed ID: 1999656
[TBL] [Abstract][Full Text] [Related]
32. Adipsin, the adipocyte serine protease: gene structure and control of expression by tumor necrosis factor.
Min HY; Spiegelman BM
Nucleic Acids Res; 1986 Nov; 14(22):8879-92. PubMed ID: 3024123
[TBL] [Abstract][Full Text] [Related]
33. Differentiation dependent biphasic regulation of adipsin gene expression by insulin and insulin-like growth factor-1 in 3T3-F442A adipocytes.
Lowell BB; Flier JS
Endocrinology; 1990 Dec; 127(6):2898-906. PubMed ID: 2249632
[TBL] [Abstract][Full Text] [Related]
34. The role of complement activation in tumour necrosis factor-induced lethal hepatitis.
Libert C; Wielockx B; Grijalba B; Van Molle W; Kremmer E; Colten HR; Fiers W; Brouckaert P
Cytokine; 1999 Aug; 11(8):617-25. PubMed ID: 10433810
[TBL] [Abstract][Full Text] [Related]
35. Effect of calcium and factor D depletion on C3 conversion by rat intestinal glycoprotein.
Winsnes R
Scand J Immunol; 1979; 9(2):135-40. PubMed ID: 424702
[TBL] [Abstract][Full Text] [Related]
36. Potency measurements of the complement system facilitated by antibodies targeting the zymogen form of complement factor D (Adipsin).
Palarasah Y; Henriksen ASL; Thiel S; Henriksen M; Hansen SWK
Mol Immunol; 2022 Jun; 146():46-49. PubMed ID: 35429907
[TBL] [Abstract][Full Text] [Related]
37. Inhibiting alternative pathway complement activation by targeting the factor D exosite.
Katschke KJ; Wu P; Ganesan R; Kelley RF; Mathieu MA; Hass PE; Murray J; Kirchhofer D; Wiesmann C; van Lookeren Campagne M
J Biol Chem; 2012 Apr; 287(16):12886-92. PubMed ID: 22362762
[TBL] [Abstract][Full Text] [Related]
38. Factor J, an inhibitor of the classical and alternative complement pathway, does not inhibit esterolysis by factor D.
González-Rubio C; González-Muñiz R; Jiménez-Clavero MA; Fontán G; López-Trascasa M
Biochim Biophys Acta; 1996 Jul; 1295(2):174-8. PubMed ID: 8695643
[TBL] [Abstract][Full Text] [Related]
39. Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications.
Subías Hidalgo M; Yébenes H; Rodríguez-Gallego C; Martín-Ambrosio A; Domínguez M; Tortajada A; Rodríguez de Córdoba S; Llorca O
Eur J Immunol; 2017 Mar; 47(3):504-515. PubMed ID: 28083930
[TBL] [Abstract][Full Text] [Related]
40. Absence of a neutralizing antibody response to humanized cobra venom factor in mice.
Ing M; Hew BE; Fritzinger DC; Delignat S; Lacroix-Desmazes S; Vogel CW; Rayes J
Mol Immunol; 2018 May; 97():1-7. PubMed ID: 29525557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
